Using a clinicopathologic and gene expression (cp-gep) model to identify stage i-ii melanoma patients at risk of disease relapse

HIGHLIGHTS

• who: Evalyn E. A. P. Mulder and collaborators from the Departments of Surgical Oncology, Erasmus MC Cancer Institute, GD Rotterdam, The NetherlandsDepartments of Pathology, Sahlgrenska University Hospital, , have published the article: Using a Clinicopathologic and Gene Expression (CP-GEP) Model to Identify Stage I-II Melanoma Patients at Risk of Disease Relapse, in the Journal: (JOURNAL)
• what: According to the model which can be applied to the primary melanoma tissue the patients were stratified into high or low risk of recurrence. The aim was to assess the 5-year recurrence-free survival (RFS) of low . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.